Ferric carboxymaltose
- Generic Name
- Ferric carboxymaltose
- Brand Names
- Injectafer
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9007-72-1
- Unique Ingredient Identifier
- 6897GXD6OE
- Background
Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013.
- Indication
Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy. It is also indicated in adult patients who have non-dialysis-dependent chronic kidney disease.
- Associated Conditions
- Iron Deficiency Anemia (IDA)
- Associated Therapies
- -
Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia
- Conditions
- Interventions
- First Posted Date
- 2009-06-29
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 30
- Registration Number
- NCT00929409
- Locations
- 🇳🇴
St Olavs Hospital, Trondheim, Norway
🇳🇴Sykehuset Innlandet HF, Lillehammer, Norway
🇳🇴Department of Obstetrics, Vestre Viken Hospital Trust, Drammen, Norway
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
- Conditions
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2012-12-21
- Lead Sponsor
- Vifor Pharma
- Target Recruit Count
- 484
- Registration Number
- NCT00810030
- Locations
- 🇦🇹
AKH Vienna, University clinic of Int Medizin III, Vienna, Austria
Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 735
- Registration Number
- NCT00704353
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT00704028
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 513
- Registration Number
- NCT00548691
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
- Conditions
- Interventions
- First Posted Date
- 2007-10-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 2018
- Registration Number
- NCT00548860
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.